Floatz logo

Lorlatinib

MET Amplification

Massachusetts General HospitalSmall moleculePhase 1/2Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the MET Amplification cohort.

Asset / SponsorPhaseRating
Crizotinib
Massachusetts General Hospital
Phase 2BB
Osimertinib
Qingdao Central Hospital
Phase 2B
Carboplatin
Guangdong Provincial People's Hospital
Phase 2CCC
VOLITINIB
Qingdao Central Hospital
Phase 2CCC
Tepotinib
Chungbuk National University Hospital
Phase 2CCC

View all 10 →

Same molecule, other indications

Lorlatinib is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
hepatocellular carcinomaDormant
BB
Indicative ·
64 / 100
View asset →
neoplastic meningitisDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →